# US 2012/0252780 A1 · Bicyclic pyridines and analogs as sirtuin modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252780 A1
- Document ID: US20120252780A1
- Status: Published application
- Kind: A1
- Application number: 13/504,134
- Filed: 2010-10-29
- Published: 2012-10-04
- Earliest claimed: 2009-10-29
- Assignees: GlaxoSmithKline LLC
- Inventors: Pui Yee Ng; Charles Blum; Lauren McPherson; Robert B. Perni; Chi B. Vu; Mohammed Mahmood Ahmed; Jeremy S. Disch
- Web page: https://patentgrep.com/patent/US20120252780A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

## Claims

### Claim 1

A compound represented by Structural Formula (I):
a tautomer, or a salt thereof, wherein:
each of Z1 and Z2 is independently selected from N and CR, wherein:
at least one of Z1 and Z2 is CR; and
each R is independently selected from hydrogen, halo, —OH, —C≡N, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —S—(C1-C2) fluoro-substituted alkyl, C1-C4 alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl; C3-C7 cycloalkyl, —(C1-C2) alkyl-N(R3)(R3), —O—CH2CH(OH)CH2OH, —O—(C1-C3) alkyl-N(R3)(R3), and —N(R3)(R3);
W is selected from —O—, —NH—, —N(C1-C4 alkyl)-, —S—, —S(O)—, —S(O)2— and —C(R6)(R6)—, and
each R6 is independently selected from hydrogen, C1-C4 alkyl and fluoro-substituted C1-C4 alkyl, or two R6 bound to the same carbon atom are taken together to form ═O,
R1 is selected from an aliphatic carbocycle and a heterocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, ═O, C3-C7 cycloalkyl, fluoro-substituted C1-C2 alkyl, —O—R3, —S—R3, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R3), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), —C(O)—N(R3)(R3), and —(C1-C4 alkyl)-C(O)—N(R3)(R3)
R2 is selected from a carbocycle and a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, C3-C7 cycloalkyl, C1-C2 fluoro-substituted alkyl, —O—R3, —S—R3, —SO2—R3, ═O, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R3), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), —C(O)—N(R3)(R3), —(C1-C4 alkyl)-C(O)—N(R3)(R3), —O-phenyl, phenyl, and a second heterocycle, and when R2 is phenyl, R2 is also optionally substituted with —O-(saturated heterocycle), 3,4-methylenedioxy, fluoro-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, or fluoro-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R2 is optionally substituted with halo, —C≡N, C1-C4 alkyl, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl, —S—(C1-C2) fluoro-substituted alkyl, —NH—(C1-C4) alkyl, and —N—(C1-C4)2 alkyl;
each R3 is independently selected from hydrogen and —C1-C4 alkyl; or
two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom selected from N, S, S(═O), S(═O)2, and O, wherein:
when R3 is alkyl, the alkyl is optionally substituted with one or more substituents selected from —OH, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), and —N(CH2CH2OCH3)2 and
when two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle, the saturated heterocycle is optionally substituted at any carbon atom with —OH, —C1-C4 alkyl, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), or —N(CH2CH2OCH3)2; and
optionally substituted at any substitutable nitrogen atom with hydrogen, —C1-C4 alkyl, fluoro-substituted C1-C4 alkyl, or —(CH2)2—O—CH3;
p is 1, 2 or 3; and
X2 is selected from —C(═O)-†, —C(═O)—O†, —C(═O)—CR4R5-†, —S(═O)-†, —S(═O)2-†, —S(═O)—CR4R5-†, —S(═O)2—CR4R5-†, —C(═S)-†, —C(═S)—CR4R5-†, —C(═O)—NH-†, —C(═S)—NH-†, —S(═O)—NH-†, —S(═O)2—NH-†, —CR4R5—NH-†, —C(═NR4)—NH-†, —C(═O)—NH—CR4R5-†, —CR4R5—NH—C(O)-†, —CR4R5—C(═S)—NH-†, —CR4R5—S(O)—NH-†, —CR4R5—S(O)2—NH-†, —CR4R5—O—C(═O)—NH-†, and —CR4R5—NH—C(═O)—O-†, wherein:
† represents where X2 is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, —CF3 and (C1-C3 alkyl)-CF3.

### Claim 2

A compound represented by structural formula (IV):
a tautomer, or a salt thereof, wherein:
each of Z1 and Z2 is independently selected from N and CR, wherein:
at least one of Z1 and Z2 is CR; and
each R is independently selected from hydrogen, halo, —OH, —C≡N, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —S—(C1-C2) fluoro-substituted alkyl, C1-C4 alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl; C3-C7 cycloalkyl, —(C1-C2) alkyl-N(R3)(R3), —O—CH2CH(OH)CH2OH, —O—(C1-C3) alkyl-N(R3)(R3), and —N(R3)(R3);
R11 is selected from halogen and R12 is selected from hydrogen, halogen, C1-C4 alkyl and fluoro-substituted C1-C4 alkyl,
each R6 is independently selected from hydrogen, C1-C4 alkyl and fluoro-substituted C1-C4 alkyl, or two R6 bound to the same carbon atom are taken together to form ═O,
R1 is selected from a carbocycle and a heterocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, ═O, C3-C7 cycloalkyl, fluoro-substituted C1-C2 alkyl, —O—R3, —S—R3, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R3), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), —C(O)—N(R3)(R3), and —(C1-C4 alkyl)-C(O)—N(R3)(R3), and when R1 is phenyl, R1 is also optionally substituted with —O-(saturated heterocycle), —O-(fluoro-substituted saturated heterocycle), C1-C4 alkyl-substituted saturated heterocycle, 3,4-methylenedioxy, fluoro-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, or fluoro-substituted 3,4-ethylenedioxy;
R2 is selected from a carbocycle and a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, C3-C7 cycloalkyl, C1-C2 fluoro-substituted alkyl, —O—R3, —S—R3, —SO2—R3, ═O, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R3), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), —C(O)—N(R3)(R3), —(C1-C4 alkyl)-C(O)—N(R3)(R3), —O-phenyl, phenyl, and a second heterocycle, and when R2 is phenyl, R2 is also optionally substituted with —O-(saturated heterocycle), 3,4-methylenedioxy, fluoro-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, or fluoro-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R2 is optionally substituted with halo, —C≡N, C1-C4 alkyl, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl, —S—(C1-C2) fluoro-substituted alkyl, —NH—(C1-C4) alkyl, and —N—(C1-C4)2 alkyl;
each R3 is independently selected from hydrogen and —C1-C4 alkyl; or
two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom selected from N, S, S(═O), S(═O)2, and O, wherein:
when R3 is alkyl, the alkyl is optionally substituted with one or more substituents selected from —OH, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), and —N(CH2CH2OCH3)2 and
when two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle, the saturated heterocycle is optionally substituted at any carbon atom with —OH, —C1-C4 alkyl, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), or —N(CH2CH2OCH3)2; and
optionally substituted at any substitutable nitrogen atom with hydrogen, —C1-C4 alkyl, fluoro-substituted C1-C4 alkyl, or —(CH2)2—O—CH3;
p is 1, 2 or 3; and
X2 is selected from —C(═O)-†, —C(═O)—Of, —C(═O)—CR4R5-†, —S(═O)-†, —S(═O)2-†, —S(═O)—CR4R5-†, —S(═O)2—CR4R5-†, —C(═S)-†, —C(═S)—CR4R5-†, —C(═O)—NH-†, —C(═S)—NH-†, —S(═O)—NH-†, —S(═O)2—NH-†, —CR4R5—NH-†, —C(═NR4)—NH-†, —C(═O)—NH—CR4R5-†, —CR4R5—NH—C(O)-†, —CR4R5—C(═S)—NH-†, —CR4R5—S(O)—NH-†, —CR4R5—S(O)2—NH-†, —CR4R5—O—C(═O)—NH-†, and —CR4R5—NH—C(═O)—O-†, wherein:
† represents where X2 is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, —CF3 and (C1-C3 alkyl)-CF3.

### Claim 3

(canceled)

### Claim 4

A compound represented by Structural Formula (VI):
a tautomer, or a salt thereof, wherein:
each of Z1 and Z2 is independently selected from N and CR, wherein:
at least one of Z1 and Z2 is CR; and
each R is independently selected from hydrogen, halo, —OH, —C≡N, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —S—(C1-C2) fluoro-substituted alkyl, C1-C4 alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl; C3-C7 cycloalkyl, —(C1-C2) alkyl-N(R3)(R3), —O—CH2CH(OH)CH2OH, —O—(C1-C3) alkyl-N(R3)(R3), and —N(R3)(R3);
W is selected from —O—, —NH—, —N(C1-C4 alkyl)-, —S—, —S(O)—, —S(O)2— and —C(R6)(R6)—, and
each R6 is independently selected from hydrogen, halogen, C1-C4 alkyl and fluoro-substituted C1-C4 alkyl, or two R6 bound to the same carbon atom are taken together to form ═O,
R1 is selected from a carbocycle and a heterocycle, wherein R1 is substituted with a spiro bicycle and R1 is optionally further substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, ═O, C3-C7 cycloalkyl, fluoro-substituted C1-C2 alkyl, —O—R3, —S—R3, —(C1-C4 alkyl)-N(R3)(R), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R), —C(O)—N(R3)(R), and —(C1-C4 alkyl)-C(O)—N(R3)(R), and when R1 is phenyl, R1 is also optionally further substituted with —O-(saturated heterocycle), —O-(fluoro-substituted saturated heterocycle), C1-C4 alkyl-substituted saturated heterocycle, 3,4-methylenedioxy, fluoro-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, or fluoro-substituted 3,4-ethylenedioxy;
R2 is selected from a carbocycle and a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, —C≡N, C1-C4 alkyl, C3-C7 cycloalkyl, C1-C2 fluoro-substituted alkyl, —O—R3, —S—R3, —SO2—R3, ═O, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —O—(C1-C4 alkyl)-N(R3)(R3), —(C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), —C(O)—N(R3)(R3), —(C1-C4 alkyl)-C(O)—N(R3)(R3), —O-phenyl, phenyl, and a second heterocycle, and when R2 is phenyl, R2 is also optionally substituted with —O-(saturated heterocycle), 3,4-methylenedioxy, fluoro-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, or fluoro-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R2 is optionally substituted with halo, —C≡N, C1-C4 alkyl, fluoro-substituted C1-C2 alkyl, —O—(C1-C2) fluoro-substituted alkyl, —O—(C1-C4) alkyl, —S—(C1-C4) alkyl, —S—(C1-C2) fluoro-substituted alkyl, —NH—(C1-C4) alkyl, and —N—(C1-C4)2 alkyl;
each R3 is independently selected from hydrogen and —C1-C4 alkyl; or
two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom selected from N, S, S(═O), S(═O)2, and O, wherein:
when R3 is alkyl, the alkyl is optionally substituted with one or more substituents selected from —OH, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), and —N(CH2CH2OCH3)2 and
when two R3 are taken together with the nitrogen atom to which they are bound to form a 4- to 8-membered saturated heterocycle, the saturated heterocycle is optionally substituted at any carbon atom with —OH, —C1-C4 alkyl, fluoro, —NH2, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, —NH(CH2CH2OCH3), or —N(CH2CH2OCH3)2; and
optionally substituted at any substitutable nitrogen atom with hydrogen, —C1-C4 alkyl, fluoro-substituted C1-C4 alkyl, or —(CH2)2—O—CH3;
p is 1, 2 or 3; and
X2 is selected from —C(═O)-†, —C(═O)—Of, —C(═O)—CR4R5-†, —S(═O)-†, —S(═O)2-†, —S(═O)—CR4R5-†, —S(═O)2—CR4R5-†, —C(═S)-†, —C(═S)—CR4R5-†, —C(═O)—NH-†, —C(═S)—NH-†, —S(═O)—NH-†, —S(═O)2—NH-†, —CR4R5—NH-†, —C(═NR4)—NH-†, —C(═O)—NH—CR4R5-†, —CR4R5—NH—C(O)-†, —CR4R5—C(═S)—NH-†, —CR4R5—S(O)—NH-†, —CR4R5—S(O)2—NH-†, —CR4R5—O—C(═O)—NH-†, and —CR4R5—NH—C(═O)—O-†, wherein:
† represents where X2 is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, —CF3 and (C1-C3 alkyl)-CF3 and when X2 is —C(═O)—NH—CR4R5-†, R4 and R5 may also be taken together to form a 3- to 6-membered saturated carbocycle or heterocycle.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is a heterocycle.

### Claim 6 (depends on 2)

The compound of claim 2, wherein R11 and R12 are each selected from halogen.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is represented by any one of the following Structural Formulae:

### Claim 12 (depends on 1)

The compound of claim 1, wherein R1 is selected from:
and wherein R1 is optionally substituted with one or more substituents independently selected from halo, C1-C4 alkyl, fluoro-substituted C1-C2 alkyl, —(C1-C4 alkyl)-N(R3)(R3), —N(R3)(R3), —C(O)—N(R3)(R3), ═O, and —O—R3.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R1 is substituted with one or more groups independently selected from —F, —Cl, —CH3, —OCH3,

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is selected from:

### Claim 15 (depends on 14)

The compound of claim 14, wherein R1 is selected from

### Claim 16 (depends on 1)

The compound of claim 1, wherein R2 is selected from:
wherein R2 is optionally substituted with one or more groups independently selected from halo, C1-C4 alkyl, —(C1-C4 alkyl)-N(R3)(R3), C1-C2 fluoro-substituted alkyl, —O—R3, —SO2—R3, —N(R3)(R3), and —O—(C1-C4 alkyl)-N(R3)(R3).

### Claim 17 (depends on 16)

The compound of claim 16, wherein R2 is optionally substituted with one or more groups independently selected from ═O, —F, —Cl, —CN, —CH3, —OCH3, —CF2H, —N(CH3)2, —CH2N(CH3)2,
—CF3, —OCF3, —OCF2H,

### Claim 18 (depends on 17)

The compound of claim 17, wherein R2 is selected from:

### Claim 19 (depends on 18)

The compound of claim 18, wherein R2 is selected from

### Claim 20 (depends on 1)

The compound of claim 1, wherein X2 is —C(═O)—NH-†.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is any one of Compound Numbers 500, 501, 502, 503, 506, 507, 508, 510, 511, 513, 514, 517, 519, 529, 531, 533, 535, 536, 537, 538, 539, 541, 547, 548, 549, 551, 554, 556, 557, 559, 560, 563, 566, 570, 571, 574, 578, 579, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 607, 608, 609, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 622, 623, 624, 625, 626, 631, 638, 639, 644, 645, 646, 647, 648, 649, 651, 652, 653, 654, 658, 659, 660, 661, 662, 663, 664, 666, 668, 669, 670, 671, 673, 675, 678, 679, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 695, 696, 697, 699, 700, 701, 702, 703, 707, 710, 711, 713, 726, 742, 748, 750, 768, 785, 786, 787, 793, 794, 795, 801, 802, 804, 805, 819, 820, 826, 827, 830, 838, 839, 840, 845, 846, 848, 849, 850, 851, 858, 861, 868, 870, 872, 873, 874, 875, 876, 878, 880, 881, 882, 883 and 887.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

A method for treating a subject suffering from or susceptible to insulin resistance, a metabolic syndrome, diabetes, or complications thereof, or for increasing insulin sensitivity in a subject, comprising administering to the subject in need thereof the composition of claim 25.

### Claim 28

(canceled)

### Claim 29 (depends on 2)

A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier or diluent.

### Claim 30 (depends on 29)

A method for treating a subject suffering from or susceptible to insulin resistance, a metabolic syndrome, diabetes, or complications thereof, or for increasing insulin sensitivity in a subject, comprising administering to the subject in need thereof the composition of claim 29.
